Ligand Pharmaceuticals LGND Kyprolis — Total revenues and income
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's kyprolis — total revenues and income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's kyprolis — total revenues and income?
- Ligand Pharmaceuticals (LGND) reported kyprolis — total revenues and income of $6.74M in Q1 2026.
- How has Ligand Pharmaceuticals's kyprolis — total revenues and income changed year-over-year?
- Ligand Pharmaceuticals's kyprolis — total revenues and income increased by 42.7% year-over-year, from $4.72M to $6.74M.
- What does kyprolis — total revenues and income mean?
- This metric represents the aggregate financial inflows generated by the Kyprolis product line, including both core product sales and associated licensing or milestone income. It serves as a comprehensive indicator of the total economic value derived from this specific pharmaceutical asset within the company's portfolio. Monitoring this figure helps investors assess the overall commercial performance and lifecycle maturity of the product.